$MNPR
Monopar Therapeutics

2024 Q2 Form 10-Q Financial Statement

#000143774924015454 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $657.8K $757.3K $871.7K
YoY Change -10.32% -13.12% 11.86%
% of Gross Profit
Research & Development $1.131M $966.1K $1.653M
YoY Change -29.08% -41.57% -1.46%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.789M $1.723M $2.525M
YoY Change -23.17% -31.75% 2.76%
Operating Profit -$1.789M -$1.723M -$2.525M
YoY Change -23.17% -31.75% 2.76%
Interest Expense $73.48K $82.17K $90.49K
YoY Change -42.69% -9.19% 19571.74%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.715M -$1.641M -$2.435M
YoY Change -22.03% -32.59% -0.9%
Income Tax
% Of Pretax Income
Net Earnings -$1.715M -$1.641M -$2.435M
YoY Change -22.05% -32.6% -0.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$0.10 -$0.19
Diluted Earnings Per Share -$0.10 -$0.10 -$0.19
COMMON SHARES
Basic Shares Outstanding 17.48M 17.45M 13.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.00M $16.03M $11.68M
YoY Change -20.38% 37.25% -34.47%
Cash & Equivalents $6.120M $7.808M $5.726M
Short-Term Investments $6.878M $8.219M $5.951M
Other Short-Term Assets $61.02K $119.0K $106.8K
YoY Change -44.46% 11.39% -44.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.180M $8.912M $11.78M
YoY Change -30.3% -24.36% -34.58%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $49.38K
YoY Change -100.0% -100.0% -8.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $49.38K
YoY Change -100.0% -100.0% -8.04%
TOTAL ASSETS
Total Short-Term Assets $7.180M $8.912M $11.78M
Total Long-Term Assets $0.00 $0.00 $49.38K
Total Assets $7.180M $8.912M $11.83M
YoY Change -30.55% -24.68% -34.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.089M $1.435M $2.888M
YoY Change -56.45% -50.3% 175.51%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.089M $1.435M $2.888M
YoY Change -56.45% -50.3% 168.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.089M $1.435M $2.888M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.089M $1.435M $2.888M
YoY Change -56.45% -50.3% 162.65%
SHAREHOLDERS EQUITY
Retained Earnings -$63.60M -$61.80M -$54.24M
YoY Change 12.77% 13.94%
Common Stock $69.64M $69.32M $13.22K
YoY Change 8.37% 524180.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.090M $7.477M $8.945M
YoY Change
Total Liabilities & Shareholders Equity $7.180M $8.912M $11.83M
YoY Change -30.55% -24.68% -34.51%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.715M -$1.641M -$2.435M
YoY Change -22.05% -32.6% -0.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.677M -$1.655M -$2.271M
YoY Change -20.21% -27.11% -7.96%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$2.420K -$983.3K -$983.4K
YoY Change -100.08% -0.01%
Cash From Investing Activities -$2.420K -$983.3K -$983.4K
YoY Change -100.08% -0.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -9.920K $3.182M $804.8K
YoY Change -101.55% 295.36% -4928.98%
NET CHANGE
Cash From Operating Activities -1.677M -$1.655M -$2.271M
Cash From Investing Activities -2.420K -$983.3K -$983.4K
Cash From Financing Activities -9.920K $3.182M $804.8K
Net Change In Cash -1.689M $541.5K -$2.461M
YoY Change -213.1% -122.01% -0.95%
FREE CASH FLOW
Cash From Operating Activities -$1.677M -$1.655M -$2.271M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17484175
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17484175
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14904497
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14904497
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
81932 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
37661 usd
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17484175
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39070
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0463781
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1000 Skokie Blvd., Suite 350
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmette
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60091
CY2024Q1 dei City Area Code
CityAreaCode
847
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
388-0349
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
MNPR
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17484175
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7807579 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7266080 usd
CY2024Q1 us-gaap Investments
Investments
985730 usd
CY2023Q4 us-gaap Investments
Investments
0 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
118987 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
66433 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
8912296 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7332513 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12646 usd
CY2024Q1 us-gaap Assets
Assets
8912296 usd
CY2023Q4 us-gaap Assets
Assets
7345159 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1435160 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1757393 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1435160 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1757393 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
17484 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
14905 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
69302864 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
65793210 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4231 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14132 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61847443 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60206217 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7477136 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5587766 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8912296 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7345159 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
966110 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1653369 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
757281 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
871675 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1723391 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2525044 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1723391 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2525044 usd
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
82165 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
90488 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1641226 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2434556 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-835 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-10800 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
19198 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33645 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1622863 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2411711 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15979816
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13105831
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5587766 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3194310 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328661 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1641226 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
18363 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7477136 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10089652 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
807338 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
476209 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2434556 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22845 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8944661 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1641226 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2434556 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
328661 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
476209 usd
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
35857 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
60842 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-311239 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-251924 usd
CY2024Q1 mnpr Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-4238 usd
CY2023Q1 mnpr Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1655423 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2271113 usd
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
983307 usd
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2958776 usd
CY2024Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
0 usd
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
1975333 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-983307 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-983443 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3192619 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
821625 usd
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
10738 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16827 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3181881 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
804798 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1652 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-10843 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
541499 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2460601 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7266080 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8186194 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7807579 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5725593 usd
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a href="#" id="notes" title="notes"></a>Note <em style="font: inherit;">1</em> </b>–<b> Nature of Business and Liquidity</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Nature of Business</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">Monopar Therapeutics Inc. (“Monopar” or the “Company”) is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar is prioritizing its focus and resources toward its radiopharmaceutical programs in discovery and development, in particular: <em style="font: inherit;">1</em>) MNPR-<em style="font: inherit;">101</em>-Zr, a clinical stage uPAR-targeted radiodiagnostic imaging agent; and <em style="font: inherit;">2</em>) MNPR-<em style="font: inherit;">101</em>-RIT, a late preclinical stage radiotherapeutic for advanced cancers.  Monopar is in the process of winding down its non-radiopharmaceutical programs including camsirubicin and its Phase <em style="font: inherit;">1b</em> clinical trial as well as MNPR-<em style="font: inherit;">202</em> and its preclinical development. The Company’s strategic focus and resources are being placed on the assets and capabilities it has been building up in the radiopharmaceutical space.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has incurred an accumulated deficit of approximately<b> </b><span style="color: rgb(0, 0, 0); font-size: 10pt;">$61.8 </span>million as of <em style="font: inherit;"> March 31, 2024</em>. To date, the Company has primarily funded its operations with the net proceeds from the Company’s initial public offering of its common stock on Nasdaq, sales of its common stock in the public market through at-the-market sales agreements, private placements of convertible preferred stock and of common stock and cash provided in the camsirubicin asset purchase transaction. Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through <em style="font: inherit;"> June 30, 2025. </em>The Company’s ability to fund its future operations, including the continued clinical development of its radiopharmaceutical programs, is dependent upon its ability to execute its business strategy, to obtain additional funding and/or to execute collaborative research agreements. There can be <em style="font: inherit;">no</em> certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations, if at all.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><i>Risks and Uncertainties</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;">The termination of the Company’s Validive clinical trial at the end of <em style="font: inherit;"> March 2023 </em>resulted in a decrease in the Company’s stock price. The closing bid price of the Company’s stock fell below <em style="font: inherit;">$1.00</em> for more than <em style="font: inherit;">30</em> consecutive trading days, and on <em style="font: inherit;"> August 28, 2023, </em>the Company received a notice from Nasdaq stating that it is out of compliance with Nasdaq listing standards giving the Company <em style="font: inherit;">180</em> days to regain compliance. On <em style="font: inherit;"> February 27, 2024, </em>the Company was granted a <em style="font: inherit;">second</em> <em style="font: inherit;">180</em>-day period to regain compliance; there can be <em style="font: inherit;">no</em> assurance that the Company will regain compliance within Nasdaq’s extended time limits and requirements. If the Company does <em style="font: inherit;">not</em> regain compliance, the Company would face delisting and it <em style="font: inherit;"> may </em>have serious adverse consequences on the Company’s ability to raise funds, which <em style="font: inherit;"> may </em>cause Monopar to delay, restructure or otherwise reconsider its operations. If it is necessary to effect a reverse stock split to attempt to cure the bid price deficiency, the impacts on the Company’s stock price are uncertain and could be adverse.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;">Market variables over which the Company has <em style="font: inherit;">no</em> control, such as inflation of product costs, higher capital costs, labor rates and fuel, freight and energy costs, as well as geopolitical events could cause the Company to suffer significant increases in its operating and administrative expenses.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;">The Russia-Ukraine war, and resulting sanctions against Russia and Russian entities or allies, have increased fuel costs and <em style="font: inherit;"> may </em>cause shipping delays. In addition, the Israel-Hamas war has created additional uncertainties. The broader economic, trade and financial market consequences of these events are uncertain at this time, which <em style="font: inherit;"> may </em>increase the cost of supplies for the Company’s clinical materials, <em style="font: inherit;"> may </em>delay the manufacture of its clinical materials, restrict the availability of radioisotopes, <em style="font: inherit;"> may </em>increase costs of other goods and services, or make it more difficult or costly to raise additional financing, any of which could cause an adverse effect on the Company’s clinical and development program and on the Company’s financial condition.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;">There remains uncertainties as to the long-term impacts of COVID-<em style="font: inherit;">19</em> or any potential resurgences thereof. The Company is unable to estimate COVID-<em style="font: inherit;">19’s</em> or any future pandemic disease's financial impact or duration in light of treatment options and potential surges of new cases from current or future COVID-<em style="font: inherit;">19</em> variants or a future pandemic or its potential impact on the Company’s current clinical trial and development programs, including COVID-<em style="font: inherit;">19’s</em> or a future pandemic's effect on drug candidate manufacturing, shipping, patient recruitment at clinical sites and regulatory agencies around the globe. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"> </p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61800000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 mnpr Insurance Premiums Dues Subscription And Software Cost Paid In Advance
InsurancePremiumsDuesSubscriptionAndSoftwareCostPaidInAdvance
10000 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents at <em style="font: inherit;">two</em> reputable financial institutions. As of <em style="font: inherit;"> March 31, 2024</em>, the balance at <em style="font: inherit;">one</em> financial institution was in excess of the $250,000 Federal Deposit Insurance Corporation (“FDIC”) insurable limit. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits since inception and management believes the Company is <em style="font: inherit;">not</em> exposed to significant risks with respect to these financial institutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15979816
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13105831
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2485535
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2745916
CY2024Q1 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
8190107 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28435 usd
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
8218542 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
6535673 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9237 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
6544910 usd
CY2023 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17484175
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2109001
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.01
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.34
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2119001
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
543578
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.3
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2119001
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y3M
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1575423
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y6M3D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
508902
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.25
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.38
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
178650 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
223273 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
264298 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
2556 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4
CY2024Q1 mnpr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice
4.24
CY2024Q1 mnpr Sharebased Compensation Arrangement By Sharebased Payment Award Options Expected To Vest Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice
3.3
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2.5 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M3D
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1641000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2435000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15980000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13106000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19

Files In Submission

Name View Source Status
0001437749-24-015454-index-headers.html Edgar Link pending
0001437749-24-015454-index.html Edgar Link pending
0001437749-24-015454.txt Edgar Link pending
0001437749-24-015454-xbrl.zip Edgar Link pending
ex_632565.htm Edgar Link pending
ex_632566.htm Edgar Link pending
ex_632567.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnpr-20240331.xsd Edgar Link pending
mnpr20240331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
mnpr-20240331_lab.xml Edgar Link unprocessable
mnpr-20240331_pre.xml Edgar Link unprocessable
mnpr20240331_10q_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mnpr-20240331_def.xml Edgar Link unprocessable
mnpr-20240331_cal.xml Edgar Link unprocessable